Alzheimer’s drug gantenerumab fails to slow decline in phase III clinical trial

Close Up Scientist using microscope in laboratory room while making medical testing and research

The pharmaceutical company Roche has announced that two phase III trials of the potential Alzheimer’s drug gantenerumab did not achieve the goal of slowing clinical decline in participants with early Alzheimer’s disease.

Amazon’s new Kindle is a great addition to your library

Previous article

Prevalence and severity of liver enzyme alterations in COVID-19 and association with patient-centered outcomes

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations